When a veterinarian prescribes Galliprant (grapiprant) for a dog suffering from osteoarthritis, pet owners are frequently told that it represents a "new class" of pain medication—one that is gentler on the stomach, kidneys, and liver than traditional nonsteroidal anti-inflammatory drugs (NSAIDs) like carprofen or meloxicam. For owners managing chronic canine joint stiffness, that positioning sounds like an ideal solution. But how safe is grapiprant in real-world clinical use, what side effects actually occur, how long can a dog remain on treatment, and does the "gentler than an NSAID" claim withstand regulatory and post-marketing scrutiny?

Galliprant (grapiprant) is an FDA-approved, once-daily oral tablet indicated for the control of pain and inflammation associated with osteoarthritis in dogs (NADA 141-455, approved March 20, 2016). Pharmacologically, grapiprant is classified as a non-cyclooxygenase (non-COX) inhibiting NSAID within the "piprant" class. Instead of inhibiting COX-1 or COX-2 enzymes to block prostaglandin synthesis, it selectively targets and blocks the prostaglandin E2 (PGE2) EP4 receptor—the primary receptor mediating osteoarthritis pain and inflammation.

Despite its targeted mechanism, grapiprant carries NSAID-class safety boundaries. On the official FDA-approved label, the primary reported adverse reactions are gastrointestinal: vomiting, diarrhea, decreased appetite, and mucoid or bloody stools, alongside potential serum chemistry changes including elevated liver enzymes (alanine aminotransferase [ALT] and serum alkaline phosphatase [SAP]) and mild decreases in serum albumin and total protein. Standard NSAID co-administration rules strictly apply: grapiprant must never be combined with aspirin, traditional COX-inhibiting NSAIDs, or corticosteroids. It is precautioned in dogs younger than 9 months of age or weighing less than 8 lbs (3.6 kg).

In our analysis of the FDA Center for Veterinary Medicine (CVM) post-marketing adverse-event database (openFDA snapshot through July 2026), we evaluated 8,225 unique spontaneous adverse-event reports involving grapiprant. In this post-marketing cohort—where the median canine patient age was 12.0 years—gastrointestinal signs were the most frequently reported adverse events (vomiting and diarrhea led all reaction terms), while the largest single non-product signal was lack of efficacy (roughly 1,200 combined reports of inadequate pain control). Smaller but clinically meaningful clusters of liver-enzyme elevations, renal-value changes, and neurologic signs (seizures) were also present, alongside product-quality complaints (abnormal or broken tablets).

Importantly, spontaneous post-marketing reports in an elderly patient population with chronic comorbidity do not prove drug causation or establish true incidence rates. However, they do demonstrate that grapiprant remains an active anti-inflammatory medication with real-world GI, hepatic, and efficacy considerations. Indeed, in May 2018, the FDA issued an official Untitled Letter to manufacturer Elanco, determining that consumer promotional materials were misbranded because they improperly minimized grapiprant's NSAID classification and GI risk profile.

Below is the complete safety, regulatory, and post-marketing data breakdown for grapiprant in dogs.

---

What the Label Says: Galliprant's Approved Indications, Mechanism, and Precautions

To evaluate grapiprant's real-world safety, we must start with the baseline established during FDA approval (NADA 141-455).

EP4 Receptor Antagonism vs. COX Inhibition

Traditional veterinary NSAIDs—such as carprofen (Rimadyl), meloxicam (Metacam), firocoxib (Previcox), and deracoxib (Deramaxx)—function by inhibiting cyclooxygenase enzymes (COX-1 and/or COX-2). By blocking COX enzymes, these drugs inhibit the cascade that converts arachidonic acid into prostaglandins. While reducing inflammatory prostaglandins provides analgesic relief, blocking COX-1 and COX-2 also depletes homeostatic prostaglandins responsible for maintaining gastric mucosal protection, renal blood flow autogenous regulation, and platelet aggregation.

Grapiprant operates down-stream of prostaglandin synthesis. It leaves COX-1 and COX-2 enzymes active, allowing normal prostaglandin production for baseline physiologic functions. However, it selectively binds and blocks the EP4 receptor—one of four subtype receptors for prostaglandin E2 (PGE2). Because PGE2 binding at the EP4 receptor is the key driver of joint pain, swelling, and cartilage degeneration in canine osteoarthritis, blocking EP4 provides targeted analgesia.

Arachidonic Acid
       │
   COX-1 / COX-2 Enzymes  ───────► [Blocked by Carprofen, Meloxicam, Firocoxib]
       │
 Prostaglandin E2 (PGE2)
       │
   EP4 Receptor  ─────────────────► [Blocked Selectively by Grapiprant (Galliprant)]
       │
Joint Pain & Inflammation

Official Label Adverse Reactions

In the controlled field study conducted for FDA approval (285 dogs evaluated for safety; 141 grapiprant-treated and 144 vehicle-control), dogs received grapiprant at the labeled dose (2 mg/kg once daily) for 28 days. The label's field-study adverse-reaction table reports:

• Vomiting: 24 grapiprant-treated dogs (~17%) versus 9 controls (~6%).
• Diarrhea / Soft Stools: 17 treated dogs (~12%) versus 13 controls (~9%).
• Decreased Appetite / Anorexia: 9 treated dogs (~6%) versus 7 controls (~5%).
• Lethargy: 6 treated dogs versus 2 controls.
• Rare buccal ulcer and a single immune-mediated hemolytic anemia case were also recorded.

A separate, larger dose-ranging field study (366 dogs) saw the same gastrointestinal pattern (diarrhea, vomiting, inappetence) plus concurrent elevations of alkaline phosphatase and alanine aminotransferase on Day 28 and dose-dependent decreases in total protein — with no clinical impact from those laboratory changes. The label-listed adverse reactions owners should watch for therefore include vomiting, diarrhea, decreased appetite, mucoid/watery/bloody stools, and decreases in serum albumin and total protein.

Critical Safety Precautions & Contraindications

The official package insert outlines several hard boundaries:

1. Age and Weight Limits: Galliprant has not been evaluated in dogs younger than 9 months of age or weighing under 8 lbs (3.6 kg). Small-breed puppies or toy dogs below this threshold must not receive grapiprant.
2. Breeding, Pregnant, or Lactating Dogs: Safety has not been established in breeding, pregnant, or lactating animals.
3. Concomitant Medication Washout (The No-Other-NSAIDs Rule): Galliprant must not be administered concurrently with aspirin, any other oral or injectable NSAID (e.g., carprofen, meloxicam, deracoxib, firocoxib), or systemic corticosteroids (e.g., prednisone, dexamethasone, triamcinolone). Combining grapiprant with COX inhibitors or steroids dramatically escalates the risk of severe gastrointestinal ulceration and renal toxicity. When switching a dog from a traditional NSAID to Galliprant (or vice versa), veterinarians recommend a mandatory washout period (typically 5 to 7 days depending on the organ function and half-life of the previous drug).
4. Pre-existing Renal, Hepatic, or Cardiac Dysfunction: Dogs with pre-existing organ failure require baseline bloodwork (CBC and serum chemistry) and cautious clinical monitoring.

---

Is Galliprant "Gentler Than an NSAID"? The 2018 FDA Warning Letter

One of the most persistent misconceptions among pet owners—and occasionally within clinical marketing—is that Galliprant is "not an NSAID" or carries zero NSAID-associated organ risk.

The FDA's May 2018 Untitled Letter to Elanco

In May 2018, the FDA Center for Veterinary Medicine Office of Surveillance and Compliance issued an official Untitled Letter to manufacturer Elanco Animal Health regarding promotional websites for Galliprant (NADA 141-455). The letter specifically called out the "15X safety" claim — noting that the underlying 9-month study used only a small number of healthy young Beagles and did not prove Galliprant was safe at overdose in the general dog population.

The FDA determined that promotional materials were misbranded under the Federal Food, Drug, and Cosmetic Act because they presented false or misleading claims regarding the drug's safety profile. Specifically, the FDA cited Elanco for:

• Promoting Galliprant with claims that implied it was completely free of traditional NSAID risks or constituted a risk-free alternative.
• Failing to present mandatory risk information with prominent placement, specifically omitting or burying the risk of gastrointestinal adverse reactions (vomiting, diarrhea, intestinal bleeding) and the potential for liver enzyme elevations.
• Obscuring the fact that while grapiprant is a non-COX inhibiting agent, it is legally and pharmacologically classified as an NSAID within the piprant class and requires the same clinical vigilance.

The FDA's regulatory action serves as a vital reminder for pet owners and veterinary professionals: while grapiprant's EP4-targeted mechanism spares COX enzymes in lab models, it remains an anti-inflammatory drug capable of causing gastrointestinal irritation and hepatic enzyme shifts in living dogs.

---

What 8,200+ FDA Post-Marketing Adverse-Event Reports Show

While pre-approval clinical trials involve controlled cohorts (typically several hundred dogs), post-marketing surveillance captures real-world usage across hundreds of thousands of patients over years of clinical practice.

We analyzed the openFDA Animal & Veterinary Adverse Event database (snapshot dated July 5, 2026), filtering for every report that listed grapiprant as an active ingredient and removing duplicates by each report's unique identification number. That yielded 8,225 unique adverse-event reports. Every count below is computed from that deduplicated set at the report grain, meaning a single report can contribute to more than one reaction term if multiple signs were recorded.

openFDA Spontaneous Adverse Event Snapshot (Grapiprant)
├── Total Unique Reports: 8,225
├── Species: Dogs (91.9%), Cats (0.2%), Unknown/Other (7.9%)
├── Patient Demographics: Median Age = 12.0 Years (IQR: 9.0–13.0)
├── Serious AE Flag: 2,287 Reports (~27.8%)
└── Outcome Distribution:
    ├── Ongoing / Unresolved: 2,565 (31.2%)
    ├── Outcome Unknown: 2,562 (31.1%)
    ├── Recovered / Normal: 1,680 (20.4%)
    ├── Euthanized: 479 (5.8%)
    ├── Recovered with Sequela: 38 (0.5%)
    └── Died: 269 (3.3%)

Patient Demographics: An Elderly Osteoarthritis Population

Of the 8,225 unique reports, 7,556 (91.9%) involved dogs (cats accounted for just 15 reports, reflecting off-label or accidental exposure, while 640 records did not specify species).

Among canine reports with recorded age data (n = 6,833), the median age was 12.0 years (mean 11.0 years; interquartile range 9.0 to 13.0 years). This demographic reality is crucial for data interpretation: the vast majority of dogs receiving Galliprant are senior or geriatric canines suffering from advanced osteoarthritis, who frequently carry concurrent age-related diseases such as chronic kidney disease, mitral valve disease, spinal spondylosis, or occult neoplasia.

Reported Adverse Reactions Breakdown

The table below lists the most frequently reported clinical signs in the openFDA dataset for grapiprant. Because a report can list several concurrent signs, the counts are not additive and their sum exceeds the report total.

Reaction Term / Sign	Reports	Clinical Context & Interpretation
Vomiting	1,429	Most frequent reaction term; expected NSAID-class GI sign.
Diarrhea	1,257	Expected NSAID-class GI sign; ranges from soft stool to severe.
Lack of Efficacy (NOS)	961	Largest non-product signal: inadequate OA pain relief.
Lethargy / Depression	~940	Systemic sign; secondary to pain, GI distress, or illness.
Elevated ALT (Alanine Aminotransferase)	509	Hepatic signal; requires baseline and periodic bloodwork.
Not Eating	468	Appetite loss; common NSAID-class and pain-related effect.
Decreased Appetite	430	Appetite loss; common NSAID-class and pain-related effect.
Bloody Diarrhea (Hematochezia)	392	Severe GI signal; indicates intestinal mucosal erosion/bleeding.
Tablets, Abnormal	369	Product-quality signal: crumbled, discolored, or broken tablets.
Weight Loss	350	Chronic NSAID use, inappetence, or underlying disease.
Elevated BUN (Blood Urea Nitrogen)	344	Renal signal; monitor alongside creatinine and urinalysis.
Elevated SAP (Alkaline Phosphatase)	317	Hepatic signal; monitor alongside ALT.
Elevated Creatinine	304	Renal signal; monitor alongside BUN and urinalysis.
Anorexia	287	Complete food refusal; overlaps the appetite-loss cluster above.
Seizure (NOS)	264	Neurologic signal; mostly in senior dogs with CNS/metabolic disease.

Grouping the Signal by Body System

Looking at related terms together makes the real-world pattern clearer:

• Gastrointestinal: Vomiting (1,429), diarrhea (1,257), and bloody diarrhea (392) are the dominant adverse-event cluster — exactly the NSAID-class GI risks the label warns about, even though grapiprant does not inhibit COX enzymes.
• Inadequate pain control (lack of efficacy): Combining "Lack of efficacy NOS" (961), "Ineffective anti-inflammatory" (140), and "Partial lack of efficacy" (91) yields roughly 1,190 reports where the core complaint was that Galliprant did not control the dog's osteoarthritis pain. (A handful of additional "lack of efficacy" terms reference co-reported parasiticides or antibiotics and are not grapiprant efficacy failures.)
• Liver: Elevated ALT (509), elevated SAP (317), and general "elevated liver enzymes" (215) combine to more than 1,000 reports with a hepatic signal — a meaningful monitoring consideration, not a trivial one.
• Kidney: Elevated BUN (344) and elevated creatinine (304) combine to roughly 650 reports with a renal-value signal.
• Neurologic: Seizure (NOS) accounts for 264 reports (with smaller numbers of related seizure-type terms), largely in elderly dogs with underlying neurologic or metabolic disease.
• Product quality: "Tablets, abnormal" (369) plus underfilling/packaging complaints (~80) make a manufacturing-and-packaging sub-signal that is separate from true drug adverse events.

Key Takeaways from the openFDA Dataset

1. Gastrointestinal Signs Are the Dominant Safety Signal

Vomiting and diarrhea lead all reaction terms by a wide margin, with bloody diarrhea adding a severe-GI subset. This is consistent with grapiprant being an NSAID by class: even though it spares COX enzymes, blocking the EP4 receptor can still perturb mucosal barrier dynamics and produce individual GI intolerance.

2. The Largest Non-Product Signal Is "It Didn't Work"

Roughly 1,190 reports describe inadequate pain control. Because grapiprant targets only the EP4 receptor, dogs with severe, multi-pathway joint inflammation or neuropathic pain components may experience incomplete analgesia compared with broad-spectrum COX inhibitors or injectable monoclonal antibodies like bedinvetmab (Librela). If a dog shows no improvement after 10–14 days, that is a common real-world outcome — not a reason to increase the dose without veterinary guidance.

3. Liver- and Kidney-Value Monitoring Is Mandatory, Not Optional

The label already calls for baseline and periodic bloodwork, and the post-marketing data shows why: more than 1,000 reports carry a liver-enzyme signal and roughly 650 a renal-value signal. Routine serum chemistry panels (ALT, SAP, BUN, creatinine, albumin, total protein) before starting and periodically during therapy remain what guidelines recommend, exactly as for any chronic NSAID.

4. Understanding the Death and Euthanasia Outcomes

The openFDA dataset includes 479 reports of euthanasia and 269 reports of death (combined ~9.1% of reports). Spontaneous adverse-event reports do not prove causation. In a population of 12-year-old dogs with terminal mobility loss, organ dysfunction, or cancer, euthanasia due to end-stage osteoarthritis progression or unrelated disease is routinely captured in post-marketing registries if the dog was taking Galliprant at the time of death. The elderly age distribution is the confounder that matters most: these outcome counts reflect a geriatric OA population, not evidence that the drug causes acute organ mortality.

---

Head-to-Head: Galliprant vs. Carprofen, Meloxicam, Librela, and Adequan

When selecting an osteoarthritis management protocol, veterinarians weigh grapiprant against several established oral and injectable alternatives:

Metric / Feature	Galliprant (Grapiprant)	Carprofen (Rimadyl)	Librela (Bedinvetmab)	Adequan (PSGAG)
Drug Class	Non-COX Piprant NSAID	COX-1/COX-2 Inhibitor NSAID	Anti-NGF Monoclonal Antibody	Disease-Modifying Osteoarthritis Drug (DMOAD)
Target Mechanism	EP4 Receptor Antagonist	COX Enzyme Inhibition	Neutralizes Nerve Growth Factor (NGF)	Glycosaminoglycan Joint Repair / Matrix Protection
Route / Frequency	Oral Tablet (Once Daily)	Oral Tablet (Once or Twice Daily)	Subcutaneous Injection (Monthly)	Intramuscular Injection (Series then maintenance)
Primary GI Risk	Mild-to-Moderate (Vomiting/Diarrhea)	Moderate-to-High (Ulceration/Bleeding)	Minimal GI Risk	Minimal GI Risk
Organ Monitoring	Baseline & Periodic Liver/Kidney Chemistry	Mandatory Baseline & 3–6 Mo Chemistry	Minimal Organ Toxicity Signal	Minimal Organ Toxicity
Steroid/NSAID Washout	Mandatory 5–7 Day Washout	Mandatory 5–7 Day Washout	No Washout Required	No Washout Required
Primary Real-World Limitation	Efficacy ceiling in severe OA	GI & Renal toxicity risk in senior dogs	Cost; potential joint pain flare	Injection administration requirement

Clinical Selection Logic

• Grapiprant vs. Carprofen / Meloxicam: Grapiprant is often preferred as a first-line oral NSAID for dogs with mild-to-moderate OA where the clinician wants to avoid COX-inhibition GI/renal stress, or for dogs that previously experienced mild stomach upset on carprofen. However, if a dog fails to respond to grapiprant within 7 to 14 days, switching to a traditional COX-inhibitor (after a proper washout) or adding an injectable agent is standard practice (read our full guide on dog arthritis treatments).
• Grapiprant vs. Librela (Bedinvetmab): Librela is a monthly injectable anti-NGF antibody that bypasses the GI tract, liver, and kidneys entirely. For senior dogs with stage 3–4 chronic kidney disease or severe NSAID intolerance, Librela offers a non-NSAID pathway (see our Librela deep dive).

---

How Long Can a Dog Stay on Galliprant? Monitoring & Stop-The-Drug Signs

Duration of Therapy

Because canine osteoarthritis is a progressive, incurable disease, Galliprant is approved for long-term daily administration. In the 9-month target-animal safety study published in the American Journal of Veterinary Research (Rausch-Derra et al.), dogs received grapiprant daily at up to 50 mg/kg — roughly 5 to 10 times the labeled tablet-equivalent dose — for nine consecutive months. No fatal toxicities occurred, though soft stools and transient albumin and total-protein decreases were noted at the higher doses. (An earlier Galliprant promotional claim of proven safety "at up to 15×" the dose was one of the statements the FDA called misleading in its 2018 letter, because that study involved only a small number of healthy young Beagles and did not demonstrate safety at overdose across the general dog population.)

Many dogs remain on daily Galliprant for months to years with excellent quality of life. However, long-term success requires active clinical oversight.

Recommended Monitoring Protocol

Veterinary consensus guidelines (AAHA Anesthesia & Analgesia / Pain Management Guidelines) recommend the following baseline and recheck schedule for any dog on chronic Galliprant therapy:

1. Baseline Evaluation (Before Starting):
   • Complete physical exam and orthopedic assessment.
   • Baseline serum chemistry panel (ALT, SAP, Total Protein, Albumin, BUN, Creatinine).
   • Urinalysis (to assess renal concentrating ability).
2. Initial Recheck (2 to 4 Weeks Post-Initiation):
   • Evaluate clinical pain scoring (mobility improvement).
   • Recheck serum liver enzymes, albumin, and renal parameters.
3. Chronic Maintenance (Every 6 Months):
   • Bi-annual bloodwork panel and clinical exam.
   • Senior dogs (>10 years) or those with borderline renal/hepatic values should be monitored every 3 to 4 months.

Galliprant Chronic Management Pathway
┌──────────────────────────┐
│  Baseline Bloodwork &    │
│   Orthopedic Assessment  │
└────────────┬─────────────┘
             │
             ▼
┌──────────────────────────┐     No Response     ┌──────────────────────────┐
│ Start Daily Galliprant   │ ──────────────────► │ Re-evaluate Pain; Check  │
│ (2 mg/kg Oral Tablet)    │   (7–14 Days)       │  Washout for Alternative │
└────────────┬─────────────┘                     └──────────────────────────┘
             │
             │ Good Response / Mild GI Tolerated
             ▼
┌──────────────────────────┐
│ 2–4 Week Clinical & Lab  │
│ Recheck (ALT/Protein)    │
└────────────┬─────────────┘
             │
             ▼
┌──────────────────────────┐
│ Bi-annual (6-Month) Lab  │
│ Monitoring & Mobility    │
└──────────────────────────┘

When to Stop Galliprant Immediately

Owners should discontinue Galliprant and contact their veterinarian if any of the following red-flag warning signs occur:

• Persistent or Severe Vomiting: Refusing food and vomiting multiple times in 24 hours.
• Black, Tarry Stools (Melena) or Bright Red Blood in Stool: Indicates active gastrointestinal bleeding.
• Complete Loss of Appetite (Anorexia): Refusing all food for more than 24 hours.
• Jaundice / Icterus: Yellowish tint to the whites of the eyes, gums, or skin (sign of acute hepatic strain).
• Unusual Lethargy or Weakness: Inability or unwillingness to stand or walk.
• Facial Swelling or Hives: Acute allergic reaction.

---

Frequently Asked Questions (FAQ)

What are the serious side effects of Galliprant?

While most side effects are mild GI signs (vomiting, soft stool), serious adverse events include severe intestinal bleeding (bloody diarrhea or tarry stools), significant liver enzyme elevations (ALT/SAP spikes), severe protein loss leading to peripheral edema, and acute allergic reactions. In openFDA data, serious adverse events represent about 28% of reported incidents, heavily influenced by an elderly patient population.

How long can a dog stay on Galliprant?

Galliprant is labeled for long-term daily management of chronic osteoarthritis. Dogs can stay on Galliprant indefinitely—months to years—provided they undergo routine veterinary monitoring (bloodwork panels every 6 months) and do not exhibit GI bleeding or organ dysfunction.

How does Galliprant make a dog feel?

When effective, Galliprant reduces joint pain and stiffness, making dogs more willing to walk, climb stairs, rise from lying down, and engage in daily activities. It does not cause sedation or alter mental awareness. If a dog becomes lethargic or depressed on Galliprant, contact your vet immediately.

Is Galliprant safer than carprofen or meloxicam?

Grapiprant spares COX-1 and COX-2 enzymes, which generally results in a lower risk of severe gastric ulceration and acute renal injury compared to traditional COX-inhibiting NSAIDs like carprofen or meloxicam. However, as the FDA confirmed in its 2018 marketing warning, Galliprant is still an NSAID and can cause GI upset and liver enzyme elevations. It is not risk-free.

What do I do if Galliprant is not working for my dog?

In openFDA data, "lack of efficacy" is the most common owner complaint. If your dog shows no mobility improvement after 10 to 14 days of daily dosing, consult your veterinarian. Do not increase the dose yourself. Your vet may recommend adding a joint supplement like PSGAGs (Adequan), combining with gabapentin or amantadine, or performing a proper 5-to-7 day drug washout before transitioning to a traditional NSAID or an anti-NGF injection like Librela.

Can Galliprant cause liver or kidney problems in dogs?

Galliprant can cause elevations in liver enzymes (ALT and SAP) and mild drops in serum albumin. While severe liver failure or acute renal injury is uncommon compared to traditional NSAIDs, pre-existing liver or kidney disease warrants baseline chemistry testing and close veterinary supervision.

---

Sources

1. FDA Center for Veterinary Medicine (CVM): Freedom of Information (FOI) Summary, NADA 141-455 (Galliprant / grapiprant tablets), Original Approval March 20, 2016. FDA FOI Summary
2. DailyMed / U.S. National Library of Medicine: GALLIPRANT (grapiprant tablet) Package Insert & Product Labeling, NADA 141-455. DailyMed Galliprant Label
3. FDA Center for Veterinary Medicine: Untitled Letter to Elanco Animal Health regarding GALLIPRANT (grapiprant) Promotional Materials (issued May 2, 2018). FDA Elanco Untitled Letter PDF
4. FDA Center for Veterinary Medicine: Animal Drug Safety-Related Labeling Changes (Galliprant, NADA 141-455, December 3, 2024). FDA Safety Label Changes
5. FDA CVM openFDA Animal & Veterinary Adverse Event Database: Open Data Portal, Grapiprant Adverse Event Dataset (snapshot dated July 5, 2026; 8,225 unique reports after deduplication). openFDA Animal Events Portal
6. American Journal of Veterinary Research (AJVR): Rausch-Derra L, Huebner M, Wofford J, Rhodes L. Evaluation of the safety of long-term, daily oral administration of grapiprant, a novel EP4 receptor antagonist, in dogs. Am J Vet Res. 2015;76(10):853-859. AJVR PubMed Reference
7. PubMed Central (PMC): Deabold KA et al. Grapiprant: A snapshot of current knowledge and clinical usefulness in canine osteoarthritis. PMC8518515, 2021. PMC8518515 Article
8. Today's Veterinary Practice: Grapiprant for Control of Osteoarthritis Pain in Dogs: Clinical Pharmacology Review. Today's Veterinary Practice